as 05-09-2025 4:00pm EST
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | PRINCETON |
Market Cap: | 4.6M | IPO Year: | N/A |
Target Price: | $38.00 | AVG Volume (30 days): | 31.5K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -9.05 | EPS Growth: | N/A |
52 Week Low/High: | $1.10 - $16.00 | Next Earning Date: | 05-16-2025 |
Revenue: | $1,000,000 | Revenue Growth: | 674.14% |
Revenue Growth (this year): | 5376.22% | Revenue Growth (next year): | N/A |
SONN Breaking Stock News: Dive into SONN Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
GlobeNewswire
23 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
The information presented on this page, "SONN Sonnet BioTherapeutics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.